Authors

Laura Finn, MD

Latest:

Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple Myeloma

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

Vaishali Sanchorawala, MD

Latest:

First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Bernard Escudier, MD, Institut Gustave Roussy

Latest:

Evolving Practice Patterns for Advanced Clear Cell Renal Cell Carcinoma

Christine Ryan, MD

Latest:

Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Siddharth Padia, MD

Latest:

Dr. Padia on the Utility of Y-90 Glass Microspheres in HCC

Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.

Yasmin Abaza, MD

Latest:

Closing Thoughts on the MDS Treatment Landscape

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

Catherine E. Lai, MD, MPH

Latest:

Challenges in Treating AML Upon First Remission

Expert perspectives on some of the challenges faced in managing the treatment of patients with AML upon first remission.

Nathaniel Ivanick, MD, FCCP

Latest:

Robotic Navigational Bronchoscopy Advances Diagnosis of Early-Stage Lung Cancer

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.

Tyler Johnson, MD

Latest:

Building Upon Scaffolds

Cancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.

Evangelia Sereti, MSc, PhD

Latest:

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Glenn J. Hanna, MD

Latest:

Dr Hanna on the FDA Approval of Toripalimab in Nasopharyngeal Carcinoma

Glenn J. Hanna, MD, discusses the significance of the FDA approval of toripalimab for patients with recurrent or metastatic nasopharyngeal carcinoma.

Arnab Basu, MD

Latest:

Dr Basu on the Potential Utility of MRD-Guided Adjuvant Therapy in RCC

Arnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.

Timothy Schmidt, MD, University of Wisconsin

Latest:

Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple Myeloma

Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.

Sohail Dhanji, MD

Latest:

Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial Cancer

Sohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.

Jennifer Scalici, MD

Latest:

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Lance Baldo, M.D., Chief Medical Officer, Adaptive Biotechnologies

Latest:

Next-Generation Sequencing Minimal Residual Disease Testing in Blood Cancer Is Needed Now More Than Ever

Sponsored Content by Adaptive Biotechnologies

Olwen Hahn, MD

Latest:

Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast Cancer

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Virginia Borges, MD

Latest:

Unmet Needs and the Future of HER2+ Breast Cancer Treatment

The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.

Byoung Chul Cho, MD

Latest:

Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLC

Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

Eloise Theisen, MSN, AGPCNP-BC

Latest:

A Primer on Rising Medical Cannabis Use in Oncology

Unsurprisingly, the use of cannabis in patients with cancer appears to be increasing as more and more states are adopting cannabis legislation, both for medical and adult use.